What's in Tris Pharma, Inc.'s pipeline?

Tris Pharma, Inc. has 15 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 6 in Phase 2, 7 in Phase 1.

Which companies overlap with Tris Pharma, Inc.'s portfolio?

Top competitors by shared drug class: Ain Shams University, Eli Lilly and Company, Jefferson Clinic, P.C., Ministry of Health & Welfare, Korea, National Institute of Mental Health (NIMH).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tris-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Tris Pharma, Inc. — Portfolio Competitive Intelligence Brief

Tris Pharma, Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 6 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amphetamine Extended Release Suspension [Dyanavel]	Amphetamine Extended Release Suspension [Dyanavel]	marketed
TRI102	TRI102	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)		Depression

Therapeutic area mix

Depression · 1
Gastrointestinal · 1
Other · 1
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Jefferson Clinic, P.C. · 1 shared drug class
Ministry of Health & Welfare, Korea · 1 shared drug class
National Institute of Mental Health (NIMH) · 1 shared drug class
New York State Psychiatric Institute · 1 shared drug class
North Dakota State University · 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tris Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Tris Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tris-pharma-inc. Accessed 2026-05-15.